Liquid Trace™
Detects Actionable Mutations in Plasma
Analyzes over 1,500 genes (DNA & RNA)
Identifies key gene amplifications, including HER2, FGFR, PI3KCA, and RAS
Identifies key fusions, MRD, HRR, HPV/EBV
Gene expression & alternative splicing
Chromosomal abnormalities including gene amplification
Matches targeted therapy options and immune therapy options to test results
Recurrence monitoring
CellSearch®
Circulating Tumor Cells
Isolates and counts cancer cells
Measures HER2 low, PDL1 or ER
FDA cleared for patients with breast, colon, prostate, gallbladder/biliary tract, and anal cancer
Measures a patients response to therapy over time through serial testing
CellSearch® is now available for patients with Multiple Myeloma and Melanoma to quantitatively monitor residual disease.
Insurance: The assay is covered by insurance and can be applied to patients with cancer.
Turn-around Time: Liquid Trace™ - 7 business days, CellSearch® - 7 business days.
Contact Us for Information or to Order:
For more information, email us at support@proteanbiodx.com, or call us at +1 (754) 242 9682
